About: Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data
Creator	José, Luis García, José Alonso, Iñigo Alonso, Romón Amunárrizágueda, Cristina Arroyo Rodríguez, José Arroyo, García Gala, José Martínez Revuelta, Eva Revuelta, Eva Turrillas, Carmen
topic	covid:d94ea8bd3ca37eac45ce078d9ed9ee4b099c73c5#this
Source	Elsevier; Medline; PMC
abstract	Abstract Introduction Therapeutic plasma exchange (TPE) is the first-line treatment for acute thrombotic thrombocytopenic purpura (TTP). Methylene blue-plasma (MBP) has been used for over 20 years, but its efficacy in this setting remains controversial. Patients and methods: this is a comparative analysis of the experience of two Centres, with different plasma products, to evaluate their efficacy in TTP. One centre used quarantine plasma (QP), and MBP the other. We performed a retrospective longitudinal study, analysing the clinical files of TTP patients of a 13-year data evaluation period. Duration of treatment and transfusion parameters, medical record, laboratory testing, concomitant medication, and survival rate, were assessed for every episode. Results During the study period, 12 (55.5 %) and 10 (45.5 %) new cases were treated with QP and MBP, respectively. There were no significant differences between the mean numbers of TPE processes, days elapsed from diagnosis to TPE, and plasma volume transfused. The QP TPE episodes of treatment were significantly associated with an increased time to recovery compared with MBP episodes of treatment (p = 0.004). Conclusion MBP was as effective as QP in the treatment of TTP patients. Since recovery was more favourable when MBP was used, we consider MBP remains a suitable alternative to treat TTP patients.
has issue date	2020-04-12(xsd:dateTime)
bibo:doi	10.1016/j.transci.2020.102771
bibo:pmid	32605805
has license	els-covid
sha1sum (hex)	d94ea8bd3ca37eac45ce078d9ed9ee4b099c73c5
schema:url	https://doi.org/10.1016/j.transci.2020.102771
resource representing a document's title	Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data
has PubMed Central identifier	PMC7152885
has PubMed identifier	32605805
schema:publication	Transfus Apher Sci
resource representing a document's body	covid:d94ea8bd3ca37eac45ce078d9ed9ee4b099c73c5#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/d94ea8bd3ca37eac45ce078d9ed9ee4b099c73c5
is schema:about of	named entity 'remains' named entity 'first-line treatment' named entity 'Quarantine' named entity 'THROMBOTIC THROMBOCYTOPENIC PURPURA' named entity 'Methylene' named entity 'Introduction' named entity 'quarantine' named entity 'Data' named entity 'plasma exchange' named entity 'TTP' named entity 'fresh frozen plasma' named entity 'Longitudinal Data' named entity 'Fresh Frozen Plasma' named entity 'Thrombotic Thrombocytopenic Purpura' named entity 'TTP' named entity 'bloodstream' named entity 'hypotensive' named entity 'Mann-Whitney' named entity 'haemolytic anaemia' named entity '10.9' named entity 'photosensitive' named entity 'plasma' named entity 'hemostasis' named entity 'virus' named entity 'pathogen' named entity 'TTP' named entity 'remission' named entity 'data set' named entity 'ADAMTS-13' named entity 'Mouvaux' named entity 'methylene blue' named entity 'data analysis' named entity 'FFP' named entity 'Student t-test' named entity 'internal validity' named entity 'Chi-square test' named entity 'hematologic disease' named entity 'immune response' named entity 'ultraviolet light' named entity 'macrophages' named entity 'plasma' named entity 'disintegrin' named entity 'standard deviation' named entity 'plasma' named entity 'treatment groups' named entity 'TTP' named entity 'quarantine' named entity 'solvent' named entity 'plasma exchange' named entity 'serum' named entity 'TTP' named entity 'monocytes' named entity 'Middle East respiratory syndrome coronavirus' named entity 'mortality rates' named entity 'genome' named entity 'hydroxyl radicals' named entity 'detergent' named entity 'replicability' named entity 'TTP' named entity 'singlet oxygen' named entity 'remission' named entity 'calcium' named entity 'TTP' named entity 'ADAMTS-13' named entity 'Cantabria' named entity 'significant difference' named entity 'relapse' named entity 'remission' named entity 'prospective study'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software